Clinical trial
Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers
NCT01796951 is registered in ClinicalTrials.gov with Vanderbilt University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers
- Lead sponsor
- Vanderbilt University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2013
- Completion date
- February 29, 2016
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
smoking, tobacco use disorder